Media Release from Diabetes UK

Does Liraglutide therapy affect the metabolic response in patients with elevated alanine aminotransferase and type 2 diabetes mellitus?

Piya Sen Gupta¹, ABCD Research Fellow KY Thong¹, M Cull¹, P Winocour², REJ Ryder¹ on behalf of the ABCD nationwide liraglutide audit contributors

¹City Hospital, Birmingham, UK

²QE 2 Hospital, Welwyn Garden City, UK

Differences in response between exenatide and liraglutide in the Association of British Clinical Diabetologists (ABCD) nationwide audits

R.E.J. Ryder¹, K.Y. Thong¹, M.L. Cull¹, A.P. Mills¹, C. Walton² on behalf of ABCD nationwide exenatide and liraglutide audits contributors

¹City Hospital, Diabetes, Birmingham, UK

²Hull Royal Infirmary, Diabetes, Hull, UK

ABCD Nationwide Exenatide and Liraglutide Audits

REJ Ryder¹ and S Gough² on behalf of the ABCD nationwide exenatide and liraglutide audit contributors

¹City Hospital, Birmingham, UK

²Oxford, UK

ABCD Nationwide Exenatide and Liraglutide Audits

Dr Bob Ryder¹ and Professor Stephen Gough² on behalf of the ABCD nationwide exenatide and liraglutide audit contributors

¹City Hospital, Birmingham, UK

²Oxford, UK

Response of HbA1c and Weight against time in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits

Ken Thong¹, Bob Ryder¹, on behalf of the ABCD nationwide exenatide and liraglutide audits contributors

¹Diabetes, City Hospital, Birmingham

The ABCD Nationwide Exenatide and Liraglutide Audits

Dr Marc Evans¹ & Dr Chris Walton² on behalf of the Association of British Clinical Diabetologists Nationwide Audit Contributors

¹?

²Hull Royal Infirmary, Hull, UK

ABCD Nationwide Exenatide and Liraglutide Audits

Dr Bob Ryder¹ and Dr Ken Thong¹ on behalf of the ABCD nationwide exenatide and liraglutide audit contributors

¹City Hospital, Birmingham, UK